Forte Biosciences (FBRX) Income from Non-Controlling Interests (2023 - 2025)
Forte Biosciences' (FBRX) quarterly Income from Non-Controlling Interests came in at -$6000.0 in Q3 2025, down 175.0% year-on-year from $8000.0 in Q3 2024, and up 45.45% on a QoQ basis from -$11000.0 in Q1 2025.
Forte Biosciences (FBRX) Income from Non-Controlling Interests (2023 - 2025) Analysis & Trends
Forte Biosciences (FBRX) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$6000.0 in Q3 2025.
- On a quarterly basis, Income from Non-Controlling Interests fell 175.0% year-over-year to -$6000.0 in Q3 2025; TTM through Sep 2025 was -$7000.0, a 216.67% decrease from a year earlier, with the FY2024 full-year figure at $7000.0, up 75.0% from the prior year.
- Income from Non-Controlling Interests for Q3 2025 stood at -$6000.0, up from -$11000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for FBRX reached as high as $10000.0 in Q4 2024 and fell as low as -$11000.0 in Q1 2025.
- Historically, Income from Non-Controlling Interests has averaged -$666.67 across 3 years, with a median of -$5000.0 in 2024.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 233.33% in 2024 and fell as far as 600.0% in 2024.
- Year by year, Income from Non-Controlling Interests stood at $9000.0 in 2023, then advanced by 11.11% to $10000.0 in 2024, then plunged by 160.0% to -$6000.0 in 2025.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$6000.0 in Q3 2025, -$11000.0 in Q1 2025, and $10000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | Forte Biosciences | 1.36 Bn | 1.31 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -6,000.00 |
| Mar 31, 2025 | -11,000.00 |
| Dec 31, 2024 | 10,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -6,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | -6,000.00 |
| Jun 30, 2023 | 1,000.00 |